α-Synuclein Aggregation in Treatment of Parkinson's Disease
Por um escritor misterioso
Descrição
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
Stress-induced p53 drives BAG5 cochaperone expression to control α-synuclein aggregation in Parkinson's disease - Figure f6
Active alpha-synuclein proteins
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Current Progress in the Development of Probes for Targeting α-Synuclein Aggregates
α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives - Alzghool - 2022 - Movement Disorders - Wiley Online Library
Interactions between iron and α-synuclein pathology in Parkinson's disease - ScienceDirect
Frontiers Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease
Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Alpha Synuclein in Parkinson's Disease Diagnostics
Exosomal transmission of α-synuclein initiates Parkinson's disease-like pathology
p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1
de
por adulto (o preço varia de acordo com o tamanho do grupo)
